
Novartis preps a 2020 launch in multiple sclerosis as 2 successful pivotal trials set stage for an assault on Roche’s new star franchise
Novartis’ Arzerra appears ready to grab a new lease on blockbuster life as the Swiss pharma giant rolls out its top-line snapshot this morning on 2 successful head-to-head studies in multiple sclerosis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.